Abstract
Intravenous immunogloblin (IGIV) contains polyclonal human antibodies that bind to Aβ aggregates, foster the dissolution of Aβ fibrils, and enhance microglia-mediated phagocytosis of amyloid deposits in vitro. We hypothesized that IGIV might reduce cognitive decline and preserve functional abilities in Alzheimer’s Disease (AD) patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
